Barbara Liskov was already breaking new ground in 1968, when she became one of the first American women to earn a doctorate in the emerging discipline of computer science. After receiving that PhD at Stanford, she went on to design several influential programming languages, including CLU, an important precursor to Java. More recently, as an Institute Professor at MIT and head of the institute’s Programming Methodology Group, she has undertaken crucial research on distributed systems, information security and complex system failure issues. She is one of fewer than 100 individuals to receive an A.M. Turing Award from the Association of Computing Machinery. In a conversation with host Ann Miura-Ko, a lecturer in Stanford’s Department of Management Science and Engineering and founding partner of the venture capital firm Floodgate, Liskov explores how she discovered the nascent field of computer science, how she recognized and surmounted a number of fundamental computing challenges, and shares her concerns and hopes about how computing will continue to transform our lives.
Related

Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.
Video
45 minutes
Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.

Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.
Video
48 minutes
Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.

Ursheet Parikh,
Mayfield
Trevor Martin,
Mammoth Biosciences
Building Biotech to Last [Entire Talk]
The keys to future success must be established at the beginning of a platform biotech company.
Video
47 minutes
Ursheet Parikh,
Mayfield
Trevor Martin,
Mammoth Biosciences
Building Biotech to Last [Entire Talk]
The keys to future success must be established at the beginning of a platform biotech company.